Drug Profile
Research programme: glycogen synthase kinase-3b inhibitors - Pfizer
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pfizer
- Class Amines; Pyridones; Pyrimidines
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in USA
- 26 Aug 2010 Early research in Undefined indication in USA (unspecified route)